

Anti-PD-L1 (Durvalumab), Human IgG1 Antibody

rev 01/21

CATALOG NO.: A2109-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a human IgG1 monoclonal antibody that is produced by recombinant DNA technology in CHO cells. The antibody is a potent antagonist of programmed cell death-ligand 1 (PD-L1) function. It inhibits the interaction of PD-L1 with PD-1 and CD80 and activates T-lymphocytes to kill cancer cells. The monoclonal antibody does not cause antibody-dependent cellular cytotoxicity. The original monoclonal antibody is approved by the FDA for the treatment of metastatic urothelial carcinoma and in combination with etoposide, carboplatin, or cisplatin for extensive-stage small cell lung cancer (ES-SCLC).

ALTERNATE NAMES: PDL1, PD-L1, PD L1, B7-H, B7H1, B7-H1, CD274, PDCD1L1, B7 homolog 1, PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: CHO cells / Human IgG1, kappa

IMMUNOGEN: Durvalumab

CAS NUMBER: 1428935-60-7

MOLECULAR WEIGHT: 146.3 kDa

FORM: Liquid

FORMULATION: In PBS buffer, pH 7.2

STORAGE CONDITIONS: Undiluted antibody solution should be stored at 4°C in the dark and avoid freezing the solution

APPLICATIONS AND USAGE: HTRF assay

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)

Anti-CD80 (Galiximab), Human IgG1, lambda Antibody (A2011)

Anti-PD-L1 (Atezolizumab), Humanized Antibody (A1305)

FOR RESEARCH USE ONLY! Not to be used on humans.